Suven Life Sciences gets NCEs patents from Israel, Macau and S Korea
New Delhi: Suven Life Sciences has received product patents from Israel, Macau and South Korea for New Chemical Entities (NCEs) used in the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2032, the Hyderabad- based company said in a statement.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven CEO Venkat Jasti said.
NCEs are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd